Join to view full profile
330 Brookline AveBoston, MA 02215
Phone+1 617-667-5288
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Steven Balk, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is a Professor of Medicine at Beth Israel Deaconess Medical Center.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1989
Harvard Medical SchoolClass of 1983
Certifications & Licensure
MA State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 11 citationsIncreased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.Larysa Poluben, Mannan Nouri, Jiaqian Liang, Shaoyong Chen, Andreas Varkaris
Cell Reports. 2025-01-28 - 1 citationsAuthor Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.Razia Rahman, Muhammed H Rahaman, Adrienne R Hanson, Nicholas Choo, Jianling Xie
British Journal of Cancer. 2024-11-01 - 5 citationsAKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer.Mannan Nouri, Andreas Varkaris, Maya Ridinger, Susan L Dalrymple, Christopher M Dennehy
Molecular Cancer Therapeutics. 2024-10-01
Press Mentions
Thank You for Your PatientsMarch 23rd, 2020
The Prostate Cancer Foundation Awards $5.5 Million to PCF Challenge Award Recipients to Advance Prostate Cancer ResearchOctober 30th, 2018
Study Identifies Gene Linked to Chemotherapy Resistance in Prostate CancerMarch 7th, 2026
Grant Support
- Androgen Receptor Action in Castration Resistant Prostate CancerBETH ISRAEL DEACONESS MEDICAL CENTER2013–2030
- WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate CancerBETH ISRAEL DEACONESS MEDICAL CENTER2023–2028
- DF/HCC Prostate SPOREDANA-FARBER CANCER INST2023–2028
- Enhancing the Efficacy of Docetaxel in Prostate CancerBETH ISRAEL DEACONESS MEDICAL CENTER2022–2027
- Prostate Cancer Vulnerabilities to BH3 Mimetic DrugsBETH ISRAEL DEACONESS MEDICAL CENTER2021–2026
